Applied Health Economics & Outcomes Research (AHEOR) is an academic discipline that establishes the efficacy of a product, service, or treatment; compares its effectiveness to other interventions; and considers its incremental cost efficiency to determine optimal clinical application and overall economic value.
The Master's of Science (MS) builds upon the foundation concepts presented in the Graduate Certificate and focuses on the advanced application of concepts necessary for the modern practice of AHEOR in research and industry settings. This option contains ten online courses and a capstone project, which is specifically designed to enhance the student’s career trajectory. This option can be completed in two years.
Learn more about the program here.
Submissions from 2023
Utility of Medicaid Expansion of Health Outcomes in Female Breast Cancer Patients: Scoping Review, Ife Bilicke
An Analysis on Prevalence, Success, and Implication of Patient Reported Outcomes in Current and Past Clinical Trials, Megan Campbell
A Scoping Review of Microwave Ablation Versus Partial Nephrectomy for Treatment of Renal Cell Carcinoma, Benjamin Odumah
Cost-Effectiveness Analysis of Canine Heartworm Preventive Products, Emi K. Saito, VMD, MSPH, MBA, DACVPM
Health Technology Assessment Decision-Making Regarding Combination Therapy to Treat Advanced Hepatocellular Carcinoma: Comparison of Appraisals in Canada and the United Kingdom, Marybeth Tran, PharmD
Budget Impact Analysis of Tirbanibulin Field Therapy for Actinic Keratosis in Adult Patients, Cornelius Wagner, PharmD, RPh
Value Proposition Development and HEOR Strategy for Abiraterone in Prostate Cancer, Amy Yang, PharmD
Submissions from 2022
Cost Analysis Of School Vision Screening Programs: Children Eye Health Initiative Of Krishna District, South India, Asha Latha Mettla
Budget Impact Analysis of Long-Acting Reversible Contraceptives for Prevention of Pregnancy in US Females of Childbearing Age, Derek Swiger, PharmD
Submissions from 2021
Machine Learning Optimization of ICU Care: A Cost-Effectiveness Model, Mario V. Fusaro, MD
Medical Affairs and Successful Medical Device Strategies: Best Practices for Return on Intelligence (ROI), Haytham Gareer, MD, MBA, PhD
The use of a Markov Cost-Effectiveness Analysis and a PRO Instrument to Inform and Evaluate the Clinical and Economic Value of Drug Interventions, Laetitia A. N'Dri, PharmD, RPh
Budget Impact Analysis of Semaglutide for Weight-loss Management in Overweight and Obese U.S. Adults, Tobin Sebastian, PharmD
Evidence For Pomalidomide In 2nd Line Treatment Of Relapse Refractory Multiple Myeloma, Ryan Thomas, PharmD
Submissions from 2020
Phyllodes Tumor of the Breast: Association Between Age, Surgical Treatment and Survival, Alberto Batista, PharmD, AHEOR Student and Karen Walsh, MS, MBA
5- and 10-Year Cost-Effectiveness of Bariatric Surgery in Super Obese, Middle-Aged Patients: A United States Perspective, R. Ditto and I. Kim
The Prevalence of Microalbuminuria in Adolescents with Obesity in United States Using the National Health and Nutrition Examination Survey (NHANES) Data 2011-2016TA 2011-2016, Fournier Janine, PharmD, AHEOR Student and Karen Walsh, MS, MBA
Clinical and Economic Value of Implementing a Geriatric Hip Fracture Program in Hospitals in the United States, A. M. Menzie and V. Maio
The Impact of Biologic Therapy on Health-related Quality of Life in Pediatric Psoriasis, Lauren Siegel, MS, AHEOR Student and Alex Niyazov, PharmD, MPH
Systematic literature review on the effect of antidepressants on sleep impairment in major depressive disorder, Jennifer Voelker, MS AHEOR Student and J McAna
Submissions from 2018
Submissions from 2017
Identification of Cognitively Impaired Patients At Risk For Development of Alzheimer's Disease: An Analysis of US Medicare Claims Data, Michele Potashman, PhD
Submissions from 2016
The Clinical and Economic Impact of Tyrosine Kinase Inhibitor Non-adherence in CML Patients within a US Integrated Healthcare System, Amir Aminimanizani, Pharm D
The Economic Value of Biosimilars, Samantha Simpson
Submissions from 2015
The Economic Impact of a Pharmacy-Based Intervention among Patients with Schizophrenia, Tony Amos
Comparative Effectiveness of SGLT2 Inhibitors vs. Sitagliptin Add-on Therapy to Metformin inType-2 Diabetes, Chris Sevald
Submissions from 2014
Direct Comparison of Apremilast and Best Supportive Care Using a Discrete Event Simulation, Zoe Clancy, PharmD
Health Technology Assessment (HTA) of Roux-en-Y Gastric Bypass compared to Sleeve Gastrectomy in obese type 2 diabetic adults, Sepehr Farahbakhshian, MS
